A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT ID: NCT06809595
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
250 participants
INTERVENTIONAL
2025-01-29
2027-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating MM120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with MM120 based on pre-specified safety and symptom severity criteria.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 - Placebo
A substance that is designed to have no therapeutic value
Placebo
A substance that is designed to have no therapeutic value
Arm 2 - 50µg MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Arm 3 - 100µg MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
A substance that is designed to have no therapeutic value
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20
Exclusion Criteria
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mind Medicine, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Preferred Research Partners, Inc.
Little Rock, Arkansas, United States
Psychedelic Science Institute
Los Angeles, California, United States
West Los Angeles VA Medical Center
Los Angeles, California, United States
Cenexel-CNS
Torrance, California, United States
Bradenton Research Center, Inc.
Bradenton, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Sheppard Pratt Health System
Towson, Maryland, United States
Adams Clinical Boston
Boston, Massachusetts, United States
Princeton Medical Institute
Princeton, New Jersey, United States
University of Cincinnati Psychiatry- Anxiety Disorders Research Program
Cincinnati, Ohio, United States
Neuro-Behavioral Clinical Research, Inc.
North Canton, Ohio, United States
Austin Clinical Trial Partners
Austin, Texas, United States
Cedar Clinical Research
Murray, Utah, United States
Core Clinical Research
Everett, Washington, United States
A-shine s.r.o.
Pilsen, , Czechia
Institut Neuropsychiatricke Pece (INEP)
Prague, , Czechia
Psyon s.r.o.
Prague, , Czechia
CMME
Paris, , France
GHU Paris Psychiatrie et Neurosciences
Paris, , France
Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin
Berlin, , Germany
OVID Clinic Berlin
Berlin, , Germany
Central Institute of Mental Health
Mannheim, , Germany
Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie
Tübingen, , Germany
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, , Poland
Department of Psychiatry, UCK
Gdansk, , Poland
Clerkenwell Health - Baker Street
London, , United Kingdom
Clerkenwell Health
London, , United Kingdom
South London and Maudsley NHS Foundation Trust of The Maudsley Hospital
London, , United Kingdom
4 Medical Clinical Solutions
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mind Medicine, Inc. Clinical Trials Info Requests
Role: CONTACT
Phone: 1-332-282-0479
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stacy Tierney
Role: primary
Keith Heinzerling
Role: primary
Walter Dunn, MD, PhD
Role: primary
Eric Folkens
Role: primary
Chanel Adams
Role: primary
Audrey Shoultz
Role: primary
Adria Trapani-Barnacz, APN
Role: primary
Heidi K Schroeder
Role: primary
Regina Leising
Role: primary
Cara Fonken
Role: primary
Janet Jimenez
Role: primary
Maria Golescu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM120-301
Identifier Type: -
Identifier Source: org_study_id